Legal / Mass tort
Mass tort marketing is a capital decision before it is a campaign.
Mass tort is the only legal category where marketing is genuinely the business model. The advertising decides the portfolio, the portfolio decides the return, and the compliance exposure sits in the acquisition rather than in the litigation.
How does mass tort client acquisition actually work?
Mass tort acquisition works on portfolio economics. A firm invests capital in advertising against a defined injury or product, screens a large number of responses down to qualifying claimants, and holds the resulting inventory through a litigation timeline that can run for years.
The marketing risk is concentrated in two places: whether the screening is rigorous enough that the inventory holds up, and whether the acquisition methods survive scrutiny. Outreach by call and text is governed by the Telephone Consumer Protection Act, email by CAN-SPAM, and every communication by the state bar rules on advertising and solicitation.
Platform policy is the practical constraint on creative. Meta does not permit an ad to assert or imply knowledge of the viewer's medical condition, which rules out the most obvious mass tort copy in the category.
Treat it as an investment with a marketing wrapper.
Mass tort acquisition commits capital against an uncertain return over a long period. Money goes out now, screening consumes more, and any recovery arrives after a litigation timeline nobody controls. That is an investment decision, and it should be made with the rigour of one rather than the enthusiasm of a campaign launch.
The questions that actually matter come before any media plan. What is the screening criteria and who applies it. What happens to a claimant who does not qualify. What the carrying cost is per file per year. Whether the firm is litigating or building inventory for someone else. What the exit looks like if the science moves against the theory.
An agency that answers none of those and proposes a media budget is selling the easy half. We would rather have the uncomfortable conversation first, including the possibility that the honest answer is not to run the campaign.
This is also why cost per lead is close to meaningless here. A cheap lead that fails screening costs more than an expensive one that qualifies, and the portfolio is judged on qualified files rather than on responses.
Where mass tort acquisition actually gets into trouble.
Every item here is a live constraint on how claimants may be contacted and what may be said. Each is linked in the sources below.
- Email and phone follow up carry their own rules. CAN-SPAM requires accurate headers, a physical postal address and a working opt out honoured promptly, and calls and texts to consumers sit under the Telephone Consumer Protection Act. Follow up sequences get built to those rules rather than retrofitted to them.
- Meta does not allow an ad to assert or imply that it knows a personal attribute of the person seeing it, including a medical or health condition, financial status or criminal history. "Depression counselling" is allowed. "Depression getting you down?" is not.
- ABA Model Rule 7.1 says a lawyer shall not make a false or misleading communication about the lawyer or the lawyer's services. Every state adopts its own version, so compliance is a state question and the responsibility sits with the firm, not the agency. We write to the stricter reading and send everything for your review before it publishes.
- No page we write for a law firm promises an outcome, predicts a recovery or compares one firm's results to another's. Past results are described as past results, with the disclaimer attached, because a communication that creates an unjustified expectation is exactly what the rule prohibits.
- Any material connection between you and someone endorsing you has to be disclosed clearly and close to the endorsement. Paying, gifting, discounting or employing someone all count as material connections.
State solicitation rules sit on top of all of this, and several states impose specific requirements on written and electronic contact with potential claimants. Anything involving outbound contact belongs with your own ethics counsel before a single message is sent.
The obvious creative is the creative that will not run.
Mass tort advertising has an instinctive form, and that form runs directly into platform policy.
The natural ad copy in this category addresses the viewer about their own medical history. Were you diagnosed with a condition after taking a product. Did you have a device implanted. Each of those asserts or implies knowledge of a personal attribute, which Meta's advertising standards do not permit.
Meta does not allow an ad to assert or imply that it knows a personal attribute of the person seeing it, including a medical or health condition, financial status or criminal history. "Depression counselling" is allowed. "Depression getting you down?" is not.
Read the full breakdown: The obvious creative is the creative that will not run.Hide the full breakdown: The obvious creative is the creative that will not run.
The compliant version describes the legal service and the subject matter without addressing the reader's circumstances. It is less immediately arresting and it is the version that runs, which makes it the more effective one by a wide margin.
Search advertising has its own constraints. Google's policies require legal advertisers to comply with applicable licensing and regulation, and health related claims attached to a product or condition bring the substantiation standard into play alongside the bar rules.
The practical consequence is that creative development in mass tort is a compliance exercise with a copywriting component, not the other way around. Building a campaign and then seeking approval is how firms lose weeks.
The step that determines whether any of this was worth doing.
Acquisition volume is easy to buy. Inventory quality is what survives.
Define qualification before you advertise
Exposure window, diagnosis criteria, documentary proof required, and exclusions. Written down, agreed, and used consistently rather than interpreted case by case.
Screen in stages
A short initial filter, then a documented intake, then records collection. Each stage costs more than the last, so the cheap filters have to do real work.
Collect the proof early
Files that sit unproven for months are the ones that fall out later, at maximum cost. Records retrieval is part of acquisition, not part of litigation.
See the remaining steps: The step that determines whether any of this was worth doing.Hide the remaining steps: The step that determines whether any of this was worth doing.
Handle the people who do not qualify
Most respondents will not, and they are still people who reached out about a health event. A clear, respectful decline is both decent and reputationally significant in a category that is watched closely.
Report by cohort, not in aggregate
Acquisition cost per qualified file, by source and by month. Blending a good month with a bad one hides exactly the information you need to decide whether to keep spending.
Results vary by market, budget, competition and other factors. Nothing here is a guarantee of a ranking, a lead volume or a revenue outcome.
What legal advertising costs generally.
LocalIQ aggregates its own customers' Google and Microsoft Ads accounts. These are whole category legal figures and are included as orientation only, since mass tort acquisition costs are driven by the specific litigation rather than by category averages.
SourceLocalIQ, Search Advertising Benchmarks, 2026
We do not publish mass tort cost per qualified file figures. The ones in circulation come from lead vendors and case acquisition firms with a direct interest in the number and no disclosed methodology.
Running your own acquisition against purchasing files.
Both are used, often together, and they carry different risks.
| Item | Your own campaigns | Purchased files |
|---|---|---|
| Control of screening | Complete | Dependent on the vendor's process |
| Cost profile | Capital up front, uncertain yield | Known price per file |
| Compliance exposure | Yours, and manageable | Yours, and harder to verify |
| Speed to volume | Slower | Immediate |
| Quality risk | Visible as it happens | Discovered later, in bulk |
| What to insist on | Cohort level reporting | Documented consent trail and screening records |
If files are purchased, the consent trail is the thing to examine hardest. How the claimant was contacted, what they consented to and whether that documentation would stand up is your exposure, regardless of who did the contacting.
Mass tort advertising is watched by people who are not claimants.
This category attracts more public scepticism than any other part of legal marketing. Journalists cover it, regulators examine it, defendants use it in argument, and the general public has seen enough daytime advertising to have formed a view.
That has a practical consequence for how a firm presents itself. Advertising that is aggressive, medically loose or emotionally manipulative does not just risk a policy rejection, it becomes evidence in a narrative about the industry that eventually reaches a jury pool.
Firms with a long term position in this work tend to advertise more conservatively than the category average, and to publish substantive material about the litigation alongside the acquisition creative. It costs a little responsiveness and buys credibility that matters when a case is being argued rather than acquired.
The same logic applies to how declined respondents are treated, and to whether the firm can explain its screening if asked. Both are reputational assets that cost almost nothing and are usually neglected.
Entering a litigation late is a marketing decision with no marketing solution.
Acquisition costs in mass tort are not stable. Early in a litigation there are few advertisers and claimant awareness is low, so responses are cheap and hard to find. In the middle there is broad awareness and heavy competition, so responses are plentiful and expensive. Late on, the qualifying population has already been contacted repeatedly and what remains is disproportionately made up of people who did not qualify the first three times.
Firms most often enter in the middle, because that is when the litigation becomes visible enough to notice. That is also the most expensive point and the one where the marginal file is weakest, which is why so many mid-cycle campaigns disappoint despite being competently run.
Read the full breakdown: Entering a litigation late is a marketing decision with no marketing solution.Hide the full breakdown: Entering a litigation late is a marketing decision with no marketing solution.
There is no media tactic that fixes late entry. Better creative, tighter targeting and a stronger landing page all help at the margin and none of them change the fact that the available population has been worked. The honest conversation is whether the economics still support entry at the price the auction currently sets, and sometimes the answer is no.
Where a firm does enter late, the defensible strategy is usually narrower: a specific injury subset, a specific geography, or a claimant group that the broad campaigns have consistently screened out. That is a smaller portfolio built deliberately rather than a large one bought at the wrong price.
What a qualified file costs, and how to tell a programme is failing.
LocalIQ's 2026 benchmarks put legal services at a $9.87 average cost per click, which is a reference point and nothing more. Mass tort acquisition costs are set by the specific litigation, the stage of the cycle and the number of advertisers in it, and a category average tells you nothing about any of those.
Define qualified as the screening criteria themselves: exposure window, diagnosis, documentary proof, exclusions and the jurisdictional position. A response that does not meet all of them is a cost rather than an asset, which is why cost per response is a misleading number and cost per qualified file is the only one worth managing to.
Read the full breakdown: What a qualified file costs, and how to tell a programme is failing.Hide the full breakdown: What a qualified file costs, and how to tell a programme is failing.
Compliance here is heavier than in any other practice area on this hub, because acquisition involves outbound contact, consent trails and claims about litigation that has not concluded. Every communication remains subject to the bar rules your state adopts, and the firm is responsible for all of it including the work of any vendor acting on its behalf.
The vendor point is the one most often underestimated. Exposure for how a claimant was contacted follows the file, which means a purchased consent trail is your problem rather than the seller's, and it should be examined rather than accepted on assurance.
How you tell it is being done badly: creative that addresses the viewer about their medical history, reporting that blends cohorts together, screening applied inconsistently, and nobody able to produce the consent documentation for a purchased file.
What we would run.
Google Ads Management
Campaigns built to clear policy review first and perform second.
Landing Page Optimization
Pages that qualify as well as convert, with a documented consent trail.
Conversion Tracking Setup
Cohort level reporting on qualified files rather than responses.
CRM Implementation
Screening stages, records status and decline reasons all visible in one place.
Meta Ads Management
Creative developed inside the personal attributes standard rather than against it.
Your website works alongside the case management system you already run.
We do not replace your case management system, we do not migrate it, and we do not ask you to change it. The site links to it from the places a client is ready to act, and embeds the vendor's own widget where the vendor publishes one. Being plain about the mechanism: that is all it is. Nothing is synced, nothing we build reads or writes your records, and the names below are systems our clients run, not partners of ours. Volume intake is the point, so the handoff usually runs into a dedicated screening platform rather than the firm's own case system, and those two do not always agree about what a qualified claimant is.
Case and practice management
The system your matters live in stays exactly where it is. Where it publishes a client portal or a payment page, the site links straight to it, so a client arrives at the thing you already pay for rather than at a second login you would have to support.
- Clio, including Clio Manage and Clio Grow
- MyCase
- Smokeball
- Filevine
- PracticePanther
- Rocket Matter
- CasePeer
- Neos, and the Needles practices still running on it
Intake and lead management
Where your intake tool publishes a hosted form, we embed it on the page somebody is reading or link straight into it. An enquiry then lands in the queue your team already works from, instead of in a second inbox that nobody has been made responsible for.
- Lawmatics
- Lead Docket
- Captorra
- Intaker
Signatures and documents
Engagement letters, retainers and fee agreements keep running through whatever you use now. The site's job is to bring somebody to the point of signing and hand over cleanly. It never holds the document.
- Docusign
- Dropbox Sign
- Adobe Acrobat Sign
What we actually change
Not the system: the path to it. Where the button sits on the page, whether it says what happens when you press it, how many taps it takes from a phone, whether it appears again at the point a client has finished reading and decided, and whether somebody who is not ready yet has a second way to reach you. That path is ours, it is measurable, and in most firm audits it is the part doing the damage.
Where the handoff is only a link
Some vendors publish an embeddable widget and some publish nothing at all. Where there is nothing to embed and no deep link worth pointing at, the site sends the visitor to your booking page or your login and stops there. That is a perfectly good outcome and we would rather say so than describe a seam we cannot remove. What we can do is make the destination unsurprising, so nobody arrives wondering whether they are still dealing with you.
Get a mass tort acquisition review.
We look at the economics before the media plan, then at whether your creative and your consent trail would survive scrutiny.
One caveat on all of that. These are descriptions of rules as they are published today, not legal advice about your situation. They differ by state and they change, sometimes quietly, so check the current wording with your own counsel or compliance officer before you rely on any of it. Where a rule touches your marketing we write to the stricter reading and send it to you for sign off before anything publishes.
Straight answers.
Why does our mass tort creative keep getting rejected?
Almost always because it addresses the viewer about their own medical history. Meta does not allow an ad to assert or imply knowledge of a personal attribute, and a health condition is squarely within that.
The compliant version describes the service and the subject matter without addressing the reader's circumstances. It clears review and therefore outperforms the version that does not run.
Should we buy files or run our own campaigns?
Many firms do both. The difference that matters is control of screening and visibility of the consent trail, because exposure for how a claimant was contacted follows the file rather than staying with the vendor.
If you purchase, insist on documented consent records and screening evidence, and examine them rather than accepting an assurance.
What outreach rules apply to contacting potential claimants?
Calls and texts to consumers sit under the Telephone Consumer Protection Act, email under CAN-SPAM, and every communication under your state bar's advertising and solicitation rules, several of which impose specific requirements on contact after an incident.
This is a question for your own ethics counsel and a compliance review before any outbound programme begins.
What should we report on, if not cost per lead?
Acquisition cost per qualified file, by source and by cohort. A cheap response that fails screening costs more than an expensive one that qualifies.
Blending months together hides the information you need. Cohort reporting is the only way to see whether a campaign is still worth funding.
How conservative should mass tort advertising be?
More conservative than the category average, if the firm intends to be in this work for a long time. This advertising is examined by journalists, regulators, defendants and eventually by jurors.
Substantive material about the litigation published alongside the acquisition creative costs a little immediate responsiveness and buys credibility where it counts.
Can you guarantee a volume of qualified claimants?
No. Volume depends on the litigation, the science, competing advertisers, platform policy and the screening criteria, and none of those are within an agency's control.
What we commit to is the economics being modelled honestly before spend begins and reported truthfully afterwards.
Where this comes from.
Primary documentation and published research behind the guidance on this page.
- American Bar Association, Model Rule 7.1: communications concerning a lawyer's services (opens in a new tab)The ABA's own page, which reproduces the rule itself.
- Illinois Courts: Rules of Professional Conduct, Article VIII (opens in a new tab)Every Illinois rule of professional conduct, each linked as the court publishes it.
- Meta Transparency Center: privacy violations and personal attributes in ads (opens in a new tab)
- FCC: unwanted calls and texts, the Telephone Consumer Protection Act (opens in a new tab)
- FTC: CAN-SPAM Act compliance guide for business (opens in a new tab)
- FTC: endorsement guides, what people are asking (opens in a new tab)
- Google Ads Help: Google Ads policies (opens in a new tab)
- LocalIQ: search advertising benchmarks (opens in a new tab)
Talk to the team
A short call, a look at how the business currently shows up, and a straight answer on what we would do first.